Sarepta Therapeutics (SRPT) Shares are Up 1.54%

Sarepta Therapeutics (SRPT) : Traders are bullish on Sarepta Therapeutics (SRPT) as it has outperformed the S&P 500 by a wide margin of 6.96% in the past 4 weeks. The bullishness in the stock continues even in the near-term as the stock has returned an impressive 1.58%, relative to the S&P 500. The stock has continued its bullish performance both in the near-term and the medium-term, as the stock is up 1.54% in the last 1 week, and is up 7.37% in the past 4 weeks. Buying continues as the stock moves higher, suggesting a strong appetite for the stock.

Sarepta Therapeutics, Inc. is up 33.94% in the last 3-month period. Year-to-Date the stock performance stands at -33.51%. The stock has recorded a 20-day Moving Average of 1.24% and the 50-Day Moving Average is 16.68%.


Sarepta Therapeutics (NASDAQ:SRPT): During Fridays trading session, Bulls were in full control of the stock right from the opening. The stock opened at $25.43 and $25.07 proved to be the low of the day. Continuous buying at higher levels pushed the stock towards an intraday high of $25.86. The buying momentum continued till the end and the stock did not give up its gains. It closed at $25.65, notching a gain of 0.83% for the day. The total traded volume was 2,015,063 . The stock had closed at $25.44 on the previous day.

Also, Equity Analysts at the Brokerage Firm, Wedbush, reiterates their rating on the shares of Sarepta Therapeutics (NASDAQ:SRPT). Wedbush has a Outperform rating on the shares. As per the latest report, the brokerage house maintains the price target to $36 per share. The rating by the firm was issued on July 20, 2016.

Sarepta Therapeutics, Inc. is a biopharmaceutical company. The Company is focused on the discovery and development of unique ribonucleic acid (RNA-targeted therapeutics for the treatment of rare, infectious and other diseases. The Company is primarily focused on advancing the development of its potentially disease-modifying Duchenne Muscular Dystrophy (DMD) drug candidates, including its lead DMD product candidate, eteplirsen, which is an antisense PMO therapeutic in Phase III clinical development for the treatment of individuals with DMD who have an error in the gene coding for dystrophin that is amenable to skipping exon 51. The Company is also developing therapeutics using its technology for the treatment of drug-resistant bacteria and infectious, rare and other human diseases.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *